Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/1751-7915.13611 http://scihub22266oqcxt.onion/10.1111/1751-7915.13611 32573950!7361915!32573950     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Microb+Biotechnol 2020 ; 13 (5): 1289-1299 Nephropedia Template TP {{tp|p=32573950|t=2020. COVID-19: From pathogenesis models to the first drug trials |pdf=|usr=}}{{32573950}} gab.com Text COVID-19: From pathogenesis models to the first drug trials JO: Microb Biotechnol http://www.kidney.de/pget.php?&tw=1&pmid=32573950 #FOAvip The number of people infected with SARS-CoV-2, and sadly dying from COVID-19, has exploded, and so the amount of literature on the novel coronavirus and the disease it causes has increased proportionately. The case numbers in some countries are beyond the epidemic peak, but the uncertainty about a second wave keeps politicians and societies under pressure. Appropriate decision-making and winning support from the population depends on precise scientific information rather than leaving the field to scaremongers of all proveniences. This mini-review is an update of earlier reports (Brussow, Microb Biotechnol 2020a;13:607; Brussow, Microb Biotechnol 2020b; https://doi.org/10.1111/1751-7915.13592). Twit Text FOAVip COVID-19: From pathogenesis models to the first drug trials ????Microb Biotechnol http://www.kidney.de/pget.php?&tw=1&pmid=32573950 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32573950 #FOAvip English Wikipedia <ref>{{Cite pmid|32573950}}</ref> COVID-19: From pathogenesis models to the first drug trials #MMPMID32573950 Brussow H Microb Biotechnol 2020[Sep]; 13 (5): 1289-1299 PMID32573950show ga The number of people infected with SARS-CoV-2, and sadly dying from COVID-19, has exploded, and so the amount of literature on the novel coronavirus and the disease it causes has increased proportionately. The case numbers in some countries are beyond the epidemic peak, but the uncertainty about a second wave keeps politicians and societies under pressure. Appropriate decision-making and winning support from the population depends on precise scientific information rather than leaving the field to scaremongers of all proveniences. This mini-review is an update of earlier reports (Brussow, Microb Biotechnol 2020a;13:607; Brussow, Microb Biotechnol 2020b; https://doi.org/10.1111/1751-7915.13592). |*Betacoronavirus[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Animals[MESH] |COVID-19[MESH] |Clinical Trials as Topic[MESH] |Coronavirus Infections/*drug therapy/*etiology[MESH] |Disease Models, Animal[MESH] |Humans[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A/physiology[MESH] |Pneumonia, Viral/*drug therapy/*etiology[MESH] |RNA, Viral/analysis[MESH] |SARS-CoV-2[MESH]COVID-19: From pathogenesis models to the first drug trials (epmc).pdf DeepDyve Pubget Overpricing